A joint research initiative between the University of Kentucky and the University of Louisville.

Research Funding Opportunities


Department of Health and Human Services

Participating Organizations
National Institutes of Health (NIH), (http://www.nih.gov)

Components of Participating Organizations
National Heart, Lung, and Blood Institute (NHLBI), (http://www.nhlbi.nih.gov)
National Cancer Institute (NCI) (http://www.cancer.gov)

Title:  Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01)

Announcement Type
New

Request for Applications (RFA) Number: RFA-HL-11-002

NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.

APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.

This FOA must be read in conjunction with the application guidelines included with this announcement in Grants.gov/Apply for Grants (hereafter called Grants.gov/Apply).

A registration process is necessary before submission and applicants are highly encouraged to start the process at least four (4) weeks prior to the grant submission date. See Section IV.

Key Dates
Release/Posted Date: March 2, 2010
Opening Date:  May 18, 2010 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): May 18, 2010
NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization). 
Application Due Date(s):  June 18, 2010
Peer Review Date(s): October/November 2010 
Council Review Date(s): January 2011
Earliest Anticipated Start Date(s): April 1, 2011 
Additional Information To Be Available Date (Activation Date): Not Applicable
Expiration Date: June 19, 2010

Due Dates for E.O. 12372
Not Applicable

Additional Overview Content

Executive Summary

  • Purpose. This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute and the National Cancer Institute,  National Institutes of Health, solicits Research Project Grant (R01) applications from institutions/organizations to identify the fundamental etiopathogenetic commonalities between lung cancer and Chronic Obstructive Pulmonary Disease (COPD) in order to characterize: (a) the genotypic and phenotypic characteristics that determine individual susceptibility; and (b) the shared biochemical, molecular, and immunological pathways involved in the origin and progression of the two diseases.
  • Mechanism of Support. This FOA will utilize the Research Project Grant (R01) award mechanism.
  • Funds Available and Anticipated Number of Awards. The NHLBI intends to commit up to $12,000,000 (Total Costs) and the NCI intends to commit up to $12,000,000 (Total Costs) over 4 years. It is anticipated that up to 8 awards will be made.
  • Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed 4 years. Direct costs in each of the years of funding may be up to $485,000 for applications that do not include a program integrating and coordinating center (PICC, see section I, Research Objectives) and up to $585,000 direct costs per year for those applications that include a PICC. The amounts will vary depending on the nature of work proposed.
  • Application Research Strategy Length: The R01 Research Strategy section may not exceed 12 pages, including tables, graphs, figures, diagrams, and charts. See Table of Page Limits.
  • Eligible Institutions/Organizations. Institutions/organizations listed in Section III, 1.A. are eligible to apply.
  • Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/ organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
  • Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application.
  • Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct. 
  • Resubmissions.  Resubmission applications are not permitted in response to this FOA.  
  • Renewals. Renewal applications are not permitted in response to this FOA. 
  • Special Date(s). This FOA uses non-standard due dates. See Receipt, Review and Anticipated Start Dates.
  • Application Materials. See Section IV.1 for application materials.
  • General Information. For general information on SF424 (R&R) Application and Electronic Submission, see these Web sites:
  • Hearing Impaired. Telecommunications for the hearing impaired are available at: TTY:  (301) 451-5936

 

 

Department of Health and Human Services

Participating Organizations
National Institutes of Health (NIH) (http://www.nih.gov)

Components of Participating Organizations
National Cancer Institute (NCI) (http://www.cancer.gov)
Office of Dietary Supplements (NIH) (http://dietary-supplements.info.nih.gov)

Title: Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)

Announcement Type
This is a reissue of PAR-06-451 <http://grants.nih.gov/grants/guide/pa-files/par-06-451.html> , which was previously released June 9, 2006.

NOTICE: Applications submitted in response to this FOA for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.

APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.

This FOA must be read in conjunction with the application guidelines included with this announcement in Grants.gov/Apply for Grants <http://www.grants.gov/Apply>  (hereafter called Grants.gov/Apply).

A registration process is necessary before submission and applicants are highly encouraged to start the process at least 4 weeks prior to the grant submission date. See Section IV.

Program Announcement (PA) Number: PAR-08-025

Catalog of Federal Domestic Assistance Number(s)
93.393, 93.394, 93.395

Key Dates
Release/Posted Date: November 19, 2007
Opening Date: February 7, 2008 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): A letter of intent is not required for the funding opportunity.
NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).
Application Submission/Receipt Date(s): March 7, 2008; July 9, 2008; November 7, 2008; March 9, 2009; July 9, 2009; November 9, 2009; March 9, 2010; July 9, 2010; November 9, 2010.
Application Review Date(s): June/July 2008; October/November 2008; February/March 2009; June/July 2009; October/November 2009; February/March 2010; June/July 2010; October/November 2010; February/March 2011.
Council Meeting Date(s): October 2008; January 2009; May 2009; October 2009; January 2010; May 2010; October 2010; January 2011; May 2011.
Earliest Start Date(s): December 2008; April 2009; July 2009; December 2009; April 2010; July 2010; December 2010, April 2011; July 2011.
Expiration Date: November 10, 2010

Due Dates for E.O. 12372

Not Applicable.

Additional Overview Content

Executive Summary

  • Purpose. This FOA is intended to promote translational research in new agent/modality development with timely exploitation of new cancer-relevant therapeutic and/or preventive strategies that involve defined molecular targets. Applications are solicited for pilot clinical trials exploring individual anticancer agents/modalities and/or their combinations in the context of specific molecular targets. Applicants may propose Phase 0, Phase I, Phase II, and/or other pilot cancer clinical trials. In addition, patient monitoring and laboratory correlative studies related to clinical trials may be proposed. Applications that explore complementary and alternative approaches for cancer prevention and/or treatment are also encouraged. Clinical trials proposed may be oriented on AIDS-associated malignancies and cancer-related nutritional interventions. Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application.
  • Mechanism of Support. This FOA will use the NIH exploratory/developmental (R21) grant mechanism for exploratory, pilot projects. Applicants planning to propose fully developed research projects supported by preliminary data should consider a related FOA (PA-07-356 <http://grants.nih.gov/grants/guide/pa-files/PA-07-356.html> ) that solicits applications for clinical therapeutic and preventive trials under the NIH research project (R01) grant mechanism.
  • Funds Available and Anticipated number of Awards: Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known.
  • Applications that do not propose a cancer clinical trial or patient monitoring or laboratory studies linked to a cancer clinical trial may be returned to applicants without being reviewed.
  • Budget and Project Period: The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $500,000 over an R21 2-year period, with no more than $250,000 in direct costs allowed in any single year.
  • An R21 award is not renewable.
  • Eligible Organizations: Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organizations (Other than Small Business); State Governments; U.S. Territory or Possession; Non-Domestic (non-U.S.) Entity (Foreign Organization); Regional Organization; Eligible agencies of the Federal government.
  • Eligible Project Directors/Principal Investigators (PDs/PIs): Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
  • Renewals. R21 awards are not renewable.
  • Resubmissions. Up to two resubmissions (formerly “revisions/amendments") of a previously reviewed R21 grant application may be submitted.
  • Application and Submission Information: Applicants may submit more than one application, provided each application is scientifically distinct.
  • Application Materials. See Section IV.1 <l>  for application materials. General Information. For general information on SF424 (R&R) Application and Electronic Submission, see these Web sites:
  • SF424 (R&R) Application and Electronic Submission Information at http://grants.nih.gov/grants/funding/424/index.htm; and
  • General information on Electronic Submission of Grant Applications at http://era.nih.gov/ElectronicReceipt/.
  • Telecommunications for the hearing impaired is available at: TTY 301-451-0088.
  • Special Receipt Dates: March 7, 2008; July 9, 2008; November 7, 2008; March 9, 2009; July 9, 2009; November 9, 2009; March 9, 2010; July 9, 2010; November 9, 2010.

For Futher Information: http://grants.nih.gov/grants/guide/pa-files/PAR-08-025.html

 
© 2007 Kentucky Lung Cancer Research Program